Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

8.680 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 115
Open 8.680
Bid (Size) 8.500 (2)
Ask (Size) 11.69 (1)
Prev. Close 8.680
Today's Range 8.680 - 8.680
52wk Range 2.410 - 12.22
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
Via Benzinga
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Via Benzinga

Performance

YTD
+139.78%
+139.78%
1 Month
-16.78%
-16.78%
3 Month
+127.23%
+127.23%
6 Month
+230.04%
+230.04%
1 Year
+131.47%
+131.47%

More News

Read More
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
Via Talk Markets
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
MindMed to Present at Upcoming April Medical Conferences
From Mind Medicine
Via Business Wire
MindMed Announces Voluntary Delisting from Cboe Canada
From MindMed
Via Business Wire
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
Via Talk Markets
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
The Next Great Biotech Boom Has Arrived
Via FinancialNewsMedia
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Via Benzinga
Exposures Product Safety
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
Via Talk Markets
Exposures Product Safety
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
From MindMed
Via Business Wire
What A Trip: Psychedelic Medicine Company MindMed Shares Rocket 50% After Positive Data
Via Talk Markets
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
Via Benzinga
Exposures Product Safety
S&P 500 Gains 1%; Kroger Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
Via Benzinga
Exposures Product Safety
What's Going On With MindMed Stock Thursday?
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.